People · Operator
Named in public records as an officer, director or promoter · active 2018–2019 · Biotech / Pharma, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Vedanta Biosciences, Inc. | — | Biotech / Pharma | Series D+ | $240.3M | $2.0B | 2018 |
| Zikani Therapeutics, Inc. | — | Pharmaceuticals | Series A | $31.7M | $232.3M | 2018 |
Christopher Viehbacher at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Christopher Viehbacher on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Lawrence Miller | 1 | 8 |
| Curt LaBelle | 1 | 7 |
| Martin Heidecker | 1 | 6 |
| Joseph Zakrzewski | 1 | 6 |
| Vikas Goyal | 1 | 5 |
| Raj Parekh | 1 | 5 |
| Andrew Myers | 1 | 4 |
| Henry Skinner | 1 | 4 |
| NEIL TIWARI | 1 | 4 |
| Markus Goebel | 1 | 4 |
| Bharatt Chowrira | 1 | 3 |
| Troy Ignelzi | 1 | 3 |
| Mary Szela | 1 | 3 |
| Henry G. Skinner | 1 | 2 |
| Anja Harmeier | 1 | 2 |
| Sumit Aggarwal | 1 | 2 |
| Edward Mascioli | 1 | 2 |
| John LaMattina | 1 | 2 |
| Bennett Shapiro | 1 | 2 |
| Raj G. Parekh | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.